Mozart Therapeutics, a Seattle, WA-based developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, raised $25M in Series A extension.
The round, which brought the total amount to $80M, saw participation from Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises. They joined existing investors ARCH Venture Partners, Sofinnova Partners, Eli Lilly & Company, MRL Ventures Fund (the early-stage therapeutics-focused fund of Merck & Co., Inc.), Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments. In conjunction with the financing, Marie-Claire Peakman, PhD, Partner of Pfizer Ventures, and Jasmina Marjanovic, PhD, Director AbbVie Ventures, will join Mozart’s Board of Directors.
The company intends to use the funds to advance its lead candidate, MTX-101, into first-in-human clinical trials and to support pipeline expansion.
Led by Katie Fanning, President and CEO, Mozart Therapeutics focuses on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is developing a portfolio of CD8 Treg modulators including MTX-101, a bispecific autoimmune checkpoint inhibitor, for the treatment of autoimmune diseases anticipating submission of an IND and initiation of a Phase 1 clinical trial for MTX- 101 in early 2024. An additional cytokine based CD8 Treg network modulator is in preclinical development.